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molecular calcification with 18F-fluoride PET/CT: will this be-
come a clinical reality and a challenge to CT calcification scoring?”
(3), published earlier on the same topic.
In addition, we take issue with a number of points made by the
authors (1). Although we agree with them that it is feasible to
detect cardiac calcifications using 18F–sodium fluoride far in
advance of visualizing this phenomenon with x-ray computed
tomography (CT), attempts to image coronary artery calcification
by visualizing the artery on CT scan are challenging for a variety of
reasons. First, it is extremely difficult to localize the coronary
arteries without the assistance of contrast dye. The administration
of x-ray contrast agent is not practical for screening of individuals
at risk, given the potential toxicity of these agents. As noted by the
investigators (1), it is necessary to assign regions of interest on
clearly visualized calcifications on CT scan for detecting the
ongoing calcification. Because the power of 18F–sodium fluoride
technology lies in its early ability to detect molecular calcification
in advance of structural abnormalities observed on CT scan,
assigning a region of interest based on coronary artery calcification
is not feasible in early disease in younger patients. Second, the
authors (1) failed to address the need for partial volume correction,
which is of importance in such small structures as coronary arteries
because loss of signal or spillover from adjacent signal may occur
when a relatively small region of interest is evaluated. Particularly,
motion artifacts due to the cardiac cycle further degrades the
spatial resolution and necessitates partial volume correction. Third,
the blood pool correction for background activity of tracer adds
further complexity and potential error.
We believe that a methodology independent of recognition of
vascular distribution, a global assessment, will be of great value in
detecting early disease before calcification is apparent on electron
beam CT imaging. The methodology that we presented in
publications predating the recent article by Dweck et al. (1)
describes a global assessment of molecular calcification detected
with 18F–sodium fluoride. Although the methodology described in
this article (1) appears to be reproducible by the investigators involved,
this may not be the case for inexperienced practitioners. A global
assessment of cardiac calcification obviates the need for partial volume
correction and therefore is essential in assessing overall calcification in
the heart. In addition, a global approach allows for delayed imaging of
2 to 3 h after the administration of sodium fluoride, which would
obviate the need for blood pool correction.
There is certainly a dire need for visualizing atherosclerotic
disease in early stages and 18F–sodium fluoride imaging may
realize this objective. Prospective, randomized clinical trials are
needed to determine the feasibility and clinical benefit of 18F–
sodium fluoride imaging for early atherosclerotic disease.
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We thank Dr. Mohler and colleagues for their interest in our study
and for their communication. We agree that prospective random-
ized clinical trials are now required to assess the clinical benefit of
cardiovascular 18F–sodium fluoride (18F-NaF) scanning.
Our paper was the first prospective description of 18F-NaF
uptake in the coronary arteries of patients specifically studied to
assess the heart (1). The highlighted paper by Behshti et al. (2)
described 18F-NaF activity within the heart in a small retrospective
cohort of patients with cancer that did not localize 18F-NaF uptake to
the coronary arteries. Their approach was to draw ellipsoid regions of
interest around the cardiac silhouette on noncontrast axial images.We
previously demonstrated that 18F-NaF activity also occurs within
noncoronary structures in the heart, most notably the aortic valve and
mitral valve annulus (1). As such, cardiac and coronary 18F-NaF
uptake cannot be considered synonymous.
There is the further question of whether it is possible to measure
18F-NaF uptake only in the coronary vessels. We demonstrated
that this is the case and is evidenced in the images and the excellent
measures of reproducibility we obtained and reported in our paper.
Most of our population with aortic stenosis had high calcium
scores, and so it was readily possible to determine the course of the
coronary arteries on both the electrocardiogram-gated and non-
gated scans. We accept that in patients with less advanced disease,
computed tomography coronary angiography will be required to
better visualize the lesions displaying increased 18F-NaF uptake.
Indeed we are currently conducting such a study and can localize
18F-NaF uptake not only to individual coronary arteries but also
individual plaques and their components.
We recognize that the issue of partial volume averaging is
important in positron emission tomography (PET) imaging.
However, the spatial resolution of PET is approximately 3 mm.
We are interested in localizing 18F-NaF activity to individual
plaques, which are commonly 20 to 30 mm long in vessels with a
diameter of 3 to 4 mm. Therefore, our approach is well within the
spatial resolution of PET, especially given the very high signal-to-
background ratio observed with 18F-NaF in the heart. Quantifying
the maximum uptake value is straightforward as reflected by our
excellent measures of reproducibility, and we are confident that our
approach will be reproduced by other groups. Indeed, several
studies have confirmed the feasibility of this approach using
18F-fluorodeoxyglucose in the coronary arteries (2,3).
Given the above, we do not believe that a volume of interest
approach to the measurement of 18F-NaF uptake in the heart is
warranted. This would result in coronary arterial 18F-NaF mea-
sures being conflated with valvular uptake. In addition, that
approach would fail to harness the high sensitivity and spatial
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resolution of PET to define the precise locations of 18F-NaF
uptake in coronary arteries.
Finally, we do agree with Dr. Mohler and colleagues that, after
further validation, 18F-NaF PET of the coronary arteries may give
unique insights into the pathophysiology of calcium deposition and
perhaps its dispersal with appropriate therapy.
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Efficiently Doing the Wrong Thing
We would like to commend Felker and Mentz (1) for their
comprehensive review of volume removal therapy for patients with
acute decompensated heart failure (ADHF). However, we also
would like to challenge their most basic assertion that “Fluid
retention and congestion are responsible for 90% of HF hospital-
izations.” Neither of the references they cite (2,3) provide data to
support that fluid retention occurs before the onset of ADHF in most
patients. In fact, more recent studies that have measured weight gain
(as a surrogate for fluid retention) show clearly that most patients gain
either no, or minimal, weight before hospitalization for ADHF (4,5)
despite increased cardiac filling pressures (5).
To account for increased cardiac filling pressures in the absence
of weight gain, volume shifts rather than volume gains must occur.
In a recent manuscript (6), we elucidate the likely mechanisms
underlying these shifts, which involve a normally compliant splanch-
nic venous system that becomes noncompliant and results in
redistribution of volume to the cardiopulmonary circulation, a
process that can occur rapidly. We also point out that even in the
minority of patients who do experience weight gain, little of the
excess fluid resides within the effective circulatory volume (approx-
imately 2.5%). The majority of patients presenting with congestion
likely have a syndrome of sympathetically mediated redistribution
of volume and diuretic resistance.
Fluid retention and congestion do not necessarily represent the
same phenomenon, and congestion most often is not due to fluid
overload. Thus, strategies aimed at removing salt and water will
necessarily be fraught with complications, including intravascular
volume depletion, activation of the renin-angiotensin system,
worsening renal function, and iatrogenically induced cardiorenal
syndrome. Therefore, we caution readers to reconsider volume
removal as the prime target of therapy for patients with ADHF.
Diagnosing the contribution of redistribution versus total body
salt and water gain emerges as the primary decision point,
followed by therapy directed at the underlying etiology of
congestion.
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We thank Drs. Dunlap and Sobotka for their interest in our recent
review on volume removal in patients with acute decompensated
heart failure (ADHF). We agree with them that redistribution of
volume (rather than increase in total body volume) may be an
important and underappreciated mechanism in patients with
acute decompensated heart failure, as our group has suggested
previously (1).
Although we welcome “outside the box” thinking in a field that
clearly would benefit from new ideas, we also suggest that the
results from recent clinical trials might dampen the enthusiasm for
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